AngioDynamics, Inc. (ANGO) Guidance & Earnings Results
On 2026-10-08 AngioDynamics, Inc. reaffirmed guidance: "FY2027 guidance reiterated; gross margin expected lower in H2 than…" — from its own filing, as read by EquiReason.
Source: SEC EDGAR filings · figures as of 2026-08-31 · read by EquiReason
ANGOAngioDynamics, Inc.Follow ANGO — free
—
Price chart with a free account
- Market cap
- 520.0M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Jan, in 72 days
What management guided
each earnings 8-K · figures checked against the filing text| Release | Direction | What they said |
|---|---|---|
| 8 Oct 26 | Reaffirmed | FY2027 guidance reiterated; gross margin expected lower in H2 than H1. · full year |
| 14 Jul 26 | Raised | FY2027 net sales $336.0M-$341.0M; Med Tech net sales growth 12%-15%; Med Device net sales growth flat; gross margin 54%-55%; adjusted EBITDA $13.0M-$16.0M; adjusted EPS ($0.29)-($0.24) · full year |
| 2 Oct 25 | Raised | Raised full year FY2026 guidance for net sales, Med Tech net sales growth, Adjusted EBITDA and Adjusted EPS · full year |
AngioDynamics, Inc. — questions
- What guidance did AngioDynamics, Inc. give?
- On 2026-10-08: "FY2027 guidance reiterated; gross margin expected lower in H2 than H1."
- When does AngioDynamics, Inc. report earnings?
- AngioDynamics, Inc.'s next earnings report is expected on 2027-01-04.
Every figure on this page comes from AngioDynamics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.